What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1
- “This Phase 1 Study will evaluate the safety, tolerability, pharmacokinectics and pharmacodynamics of XmAb412 in healthy adult participants”In the company’s words, NCT07713485 on ClinicalTrials.gov
Other drugs for Not Applicable - Healthy Adult Participants
- ObefazimodAbivax S.A. · Phase 3
- TofacitinibPfizer · Phase 3
- RisankizumabAbbVie · Phase 3
- UpadacitinibAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
Coming up1
- Aug 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovCompletion date moved: 2027-05 to 2027-08 · ClinicalTrials.gov NCT07713485
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Aug 2027 | Study of XmAb412 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026